Alkeus Pharmaceuticals, Inc.
Biotechnology ResearchView the employees at
Alkeus Pharmaceuticals, Inc.-
Chris Adams Board member, entrepreneur, mentor & advisor
-
Cambridge
-
Top 5%
Tanisha Rungta Intern @ Alkeus Pharma | Freshman @ Boston University-
Boston, Massachusetts, United States
-
Rising Star
Aria Cohen Head of Market Access at Alkeus Pharmaceuticals>>> Ground Up Function Builds | Product Launches | Team & Culture Development | Market Access & Payer Marketing Strategy Creation-
Greater Boston
-
Rising Star
Amanda Harring-Abbott Clinical Operations Leader-
Boston, Massachusetts, United States
-
Rising Star
Monica Hennessey, MPH Recent MPH Graduate in Epidemiology & Biostatistics-
Boston, Massachusetts, United States
-
Rising Star
Overview
Join our growing team! Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease.
-